Abstract
In order to help guide treatment, antifungal susceptibility testing is often performed in clinical microbiology laboratories. The results of these in vitro assays are used by clinicians to change therapy should resistance be detected, continue with current regimens with susceptible results, and as an aide in determining possible reasons for treatment failure. Antifungal susceptibility testing can be performed against dermatophytes, although fewer assay formats are recommended for these types of fungi compared to yeasts and molds. In addition, clinical breakpoints and epidemiologic cut-off values are not currently available for dermatophytes to help with the interpretation of these results. However, recently studies have demonstrated that reduced in vitro susceptibility to terbinafine, an allylamine commonly used in the treatment of dermatophyte infections, may be associated with clinical failures.
Original language | English (US) |
---|---|
Title of host publication | Dermatophytes and Dermatophytoses |
Publisher | Springer International Publishing |
Pages | 401-414 |
Number of pages | 14 |
ISBN (Electronic) | 9783030674212 |
ISBN (Print) | 9783030674205 |
DOIs | |
State | Published - Jun 8 2021 |
Keywords
- Allylamines
- Antifungal susceptibility testing
- Azoles
- Broth microdilution
- Clinical breakpoint
- Dermatophytes
- Epidemiologic cut-off value
- Resistance
ASJC Scopus subject areas
- General Medicine
- General Immunology and Microbiology
- General Agricultural and Biological Sciences
- General Biochemistry, Genetics and Molecular Biology